INTRODUCTION
For both type 1 and type 2 diabetes, an essential component of ongoing clinical and self-care management of diabetes is sufficient and accurate glycemic control, which is critical in preventing or postponing complications resulting from diabetes, such as heart disease, kidney disease, nerve damage, and peripheral vascular disease [1, 2] . The most common means for measuring glycemic control is by monitoring glycated hemoglobin (HbA 1c ), which gives an average of the blood glucose over 3 months. A limitation of this method is that measuring HbA 1c levels does not tell patients what their blood glucose levels are on a regular, daily basis. Self-monitoring by testing for urinary glucose is one method of checking if blood glucose is high, but the limitation of this test is that it lacks the proven accuracy of other methods. A more precise reading can be captured by blood testing, which is performed by pricking the skin to obtain a drop of blood, placing that sample on a testing strip, and gauging the result with a discrete meter. This method, called selfmonitoring of blood glucose (SMBG), is quite flexible and convenient in that it can be done at various points throughout the day, prior to or following meals, or before or after physical activity, allowing patients to be constantly informed of their insulin levels [2] .
SMBG in patients with diabetes who use insulin may contribute to improved glycemic control and reduced hypoglycemia by allowing self-adjustments of insulin dose to be made based on meter readings. SMBG is recognized as a core component of effective diabetes selfmanagement for insulin users throughout the world by major international organizations such as the American Diabetes Association (ADA) and the International Diabetes Federation (IDF) [3] [4] [5] [6] . SMBG is recommended by the Canadian Diabetes Association. The Canadian guidelines, while stating that the frequency of SMBG should be determined on an individual level, conclude that SMBG is an essential part of diabetes management for patients with type 1 diabetes and state that the benefits and optimal frequency are less clear for type 2 [7] .
Patient self-management is a key element in the control of diabetes, and is one of the most challenging regimens of any chronic illness [8] .
People with diabetes are asked to perform SMBG, manage multiple medications, maintain foot hygiene, adhere to diet and meal plans, and engage in exercise programs [9] . While for some insulin users SMBG is an important component of diabetes care, it poses a significant inconvenience/burden on the patient, in addition to the significant and well-documented economic costs [10] [11] [12] [13] . 
Inclusion Criteria
To be selected into the study population, subjects met each of the following inclusion criteria:
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Exclusion Criteria
Patients were excluded from the study population if they met any of the following exclusion criteria: they were aged less than 4 years on their index date; they had prescriptions for more than one category of insulin (excluding basal-bolus combination as described above, see Appendix Table 4 ) within the first 30 days immediately following their index date (including the index date). Patients who had two different types of insulin at baseline (with the exception of basalbolus combination) were also excluded, in order to avoid incorrectly attributing outcome behaviors to specific insulin groups (misclassification).
Measurements
All of the following measures were provided for the overall patient cohort, as well as the four specific subsets of insulin therapy type (basal, bolus, premixed, basal-bolus; see Appendix Table 4): demographic and clinical characteristics, blood glucose testing frequency and associated costs, and insulin and oral antidiabetic (OAD) medications costs (see Appendix Table 5 ).
Baseline Patient Demographic and Clinical Characteristics
The following patient demographic characteristics were measured as of the patient's index date or during his/her 6-month pre-index period, except as noted.
• Gender.
• Age group (4-17, 18-34, 35-54, 55-64, or C65 years) as of their index date.
• Type of patient, based on his/her insulin utilization.
• Diabetes type proxy: (1) insulin only (type 1) or (2) insulin and OADs (type 2). The available data elements only allowed for differentiation based on the presence or absence of OADs.
• Type of payer (private or public).
• Province for private drug plans.
• New or continuing insulin therapy, based on the presence of any insulin in the pre-index period.
• Total drug utilization costs for all conditions, including all patient comorbidities, during the patient's 6-month pre-index period, not including the index date, as a broad severity measure. For continuing patients, this measure includes diabetes-related costs.
Of note is that the IMS Brogan dataset does not contain diagnosis codes. Therefore, the overall burden of comorbid illnesses was inferred based on the total cost of claims for medications unrelated to diabetes.
Blood Glucose Testing
Patients' frequency of blood glucose testing was monitored throughout their 12-month postindex follow-up period through claims for blood glucose test strips reimbursed by public or private drug plans. Visits to outpatient clinics or to laboratory/diagnostic centers for the blood glucose testing cannot be tracked using IMS Brogan data, so that utilization was not captured in this study.
Frequency of blood glucose testing is classified using descriptive statistics (mean, standard deviation, and median), and was stratified by the following variables: (1) patients' insulin type, and (2) patients' payer type (public or private).
SMBG and Diabetes-Related Pharmacy Costs
The total costs during the 12-month follow-up period were assessed, focusing on blood glucose testing strip costs, insulin therapy costs, and costs associated with OAD medications.
Cost of test strips and the drug costs were calculated by multiplying the number of units dispensed by the unit price. For the private drug plans, the wholesale price was used as a unit price, while for the public drug plans, the provincial formulary price was used as a unit price. The source of the unit prices is Delta PA. Delta PA is an online application that provides convenient access to current and historical drug prices.
Sources of data include wholesale, Association québécoise des pharmaciens propriétaires (AQPP), and provincial formularies. All formulary prices are available on their respective websites.
Specific blood glucose testing costs were summarized to a total cost, as were costs specifically related to insulin and OAD therapy.
Statistical Analysis
The study population's baseline demographic and clinical characteristics were described using 
RESULTS

Demographics and Clinical Characteristics
Among 326,838 patients in the database with at least two claims for insulin between Average total pre-index pharmacy costs ranged from $1,200 for bolus only to $1,431 for premixed, with an overall cohort average of $1,346.
Blood Glucose Testing
The overall mean number of pharmacy-based blood glucose tests in the 12-month follow-up period was 1,094 (3.0 tests per day), ranging from 890 tests in the premixed group to 1,413 in the bolus group (Fig. 2) . Patients using premixed insulin had a significantly lower mean number of annual blood glucose tests The overall cohort had an average annual pharmacy cost of $2,068 attributable to insulin treatments, blood glucose test strips, and OADs.
The average cost for pharmacy-related blood glucose testing was $860 over the 1-year followup period (Table 2) . With an overall mean utilization of pharmacy-based blood glucose testing of 1,094 strips per year, the average cost per testing strip was $0.79. Among patients in private and public drug plans, the mean utilization of pharmacy-based blood glucose testing was 899 and 1,211 strips per year, respectively, while the average cost per testing strip was $0.82 and $0.77, respectively. Annual blood glucose testing costs accounted for 37.7% of total insulin-related costs for the basal insulin group, compared with 52.8% for bolus, 41.4% for premixed, and 41.5% for basal-bolus (Table 3) .
Compared with the basal insulin group, the premixed group had significantly lower average pharmacy costs over the 1-year period ($1,639 for premixed, $1,960 for basal, P\0.0001). Both the bolus-only group ($2,106, P = 0.0001) and the basal-bolus group ($2,546, P\0.0001) had significantly higher annual total diabetes-related pharmacy costs compared to the basal-only group.
Test Strip Utilization
Over the 1-year follow-up period, patients receiving basal-bolus insulin had 11.6 prescriptions for blood glucose testing strips, compared with 10.8 prescriptions for the bolus group, 9.0 for the basal group, and 8.0 for the premixed group (data not shown). Table 2 Mean overall pharmacy costs, by insulin regimen type While this study may be unique in its focus on SMBG costs relative to diabetes-related costs, previous studies have measured outcomes with differing objectives. An economic survey to evaluate the direct costs among families of patients with type 1 diabetes found that the largest economic burden was due to SMBG expenses, which represented 53% of the total annual diabetes-related costs [20] . While the surveillance-based methodology of that study differs from this study's approach, the similarity in the proportion of total costs attributable to SMBG is noteworthy. A 2010 study that also used the Canadian-based Brogan claims-level database found that, among insulin-only users, daily SMBG strip utilization averaged 2.76 in the Ontario Public Drug plan and 3.18 in private plans, similar to this study's finding of 3.00 strips per patient per day [17] . Another study using the Norwegian Prescription
Database found that 70% of the study's diabetic population practiced SMBG, with an average of 1.7 strips per day [18] . One percent of patients used 10 or more strips per day, accounting for 8% of their total costs. Our analysis identified higher average strip utilization per day (3.00 strips) among all insulin type patients, though ours required a year of persistent insulin utilization, unlike the Norwegian analysis.
Limitations
A limitation of this study is that outpatient care costs, such as those for laboratory and radiology tests, and inpatient care events (such as the number and length of hospitalizations)
could not be evaluated using this dataset. Diabetes-related complications were also not identified, due to the absence of diagnosis details within the database. Another limitation related to the lack of diagnosis codes is that As this analysis was limited to an insured insulin-dependent population in Canada, the economic impact of SMBG in an uninsured population, as well as among patients using OAD medications rather than insulin, cannot be adequately assessed, and represents a suitable topic for future studies.
It should also be noted that a subset of patients in the bolus insulin regimen may have been using insulin pumps, and adjustments for pump users were not incorporated into the analysis. Additionally, to the extent that patients switch their insulin type during the follow-up period, a portion of patients in this study may potentially be misclassified according to therapy type, though such behavior is assumed to be nondifferential across subgroups.
Outpatient 
CONCLUSION
This study shows that SMBG constitutes over 40% of the diabetes-related pharmacy costs for insulin users, and as such warrants further study to recognize the impact on both patients and healthcare reimbursement systems. 
ACKNOWLEDGMENTS
